Advanced search

  • Clinical Diabetology
  • Online first Expert Opinion on Cardio-Renal-Metabolic Approach to Management of Adults with Type 2 Diabetes Mellitus Using Oral Semaglutide: An Indian Perspective
Online first
Guidelines / Expert consensus
Published online: 2025-03-14

open access

View PDF Download PDF file
Page views 91
Article views/downloads 67
Get Citation

Connect on Social Media

Connect on Social Media

Expert Opinion on Cardio-Renal-Metabolic Approach to Management of Adults with Type 2 Diabetes Mellitus Using Oral Semaglutide: An Indian Perspective

Rajesh Rajput1, J.J. Mukherjee2, Manoj Chawla3, Sujoy Majumdar4, Sonali Patange5, Supratik Bhattacharyya6, Rajeev Chawla7, K.N. Manohar8, Rakhi Malhotra9, Sandeep Suri10, Vivek Raskar11, A.H. Zargar12, Sanjeev Phatak13, Banshi Saboo14, A.K. Das15
DOI: 10.5603/cd.103785

Abstract

Objective: This study aims to evaluate the efficacy and safety of oral semaglutide in managing type 2 diabetes (T2D) through a cardio-renal-metabolic approach tailored for the Indian context. Materials and methods: A literature review was conducted using PubMed and Google Scholar, focusing on systematic reviews, meta-analyses, and randomized controlled trials related to oral semaglutide. Findings were discussed at the 16th National Insulin and Incretin Summit (NIIS) on November 19, 2022, where an expert panel developed guidelines based on collective insights and live opinion polls. Results/Key findings: The expert committee recommends oral semaglutide for adults with T2D due to its effectiveness in lowering blood glucose and promoting weight loss. It can be used alone or with other oral anti-diabetic agents, except dipeptidyl peptidase 4 inhibitors (DPP-4i). The drug is safe for those with cardiovascular disease or chronic kidney disease (CKD). Common gastrointestinal side effects are typically mild. Administration requires fasting for 30 min after dosing. Gradual dose escalation is advised to minimize side effects, and patients should be counseled on potential interactions with other medications and pregnancy considerations. 

Keywords: semaglutidetype 2 diabetesglucagon 1 receptor agonist

Article available in PDF format

View PDF Download PDF file

References

  1. Magliano DJ, Boyko EJ, IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS. 10th ed. Brussels: International Diabetes Federation. http://www.ncbi.nlm.nih.gov/books/NBK581934/ (1.08.2024).
  2. Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021; 69(11): 2932–2938.
    CrossRefPubMed
  3. Anjana RM, Unnikrishnan R, Deepa M, et al. ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023; 11(7): 474–489.
    CrossRefPubMed
  4. India Council of Medical Research. ICMR guidelines for the management of type 2 diabetes 2018. https://main.icmr.nic.in/sites/default/files/guidelines/ICMR_GuidelinesType2diabetes2018_0.pdf (29.09.2023).
  5. American Diabetes Association. Abridged for Primary Care Providers. Clin Diabetes. 2022; 41(1): 4–31.
    CrossRefPubMed
  6. Pantalone KM, Wells BJ, Chagin KM, et al. Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System. Diabetes Care. 2016; 39(9): 1527–1534.
    CrossRefPubMed
  7. Carls G, Huynh J, Tuttle E, et al. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes Ther. 2017; 8(4): 863–873.
    CrossRefPubMed
  8. Mansour A, Mousa M, Abdelmannan D, et al. Microvascular and macrovascular complications of type 2 diabetes mellitus: Exome wide association analyses. Front Endocrinol (Lausanne). 2023; 14: 1143067.
    CrossRefPubMed
  9. de Jong M, Woodward M, Peters SAE. Duration of diabetes and the risk of major cardiovascular events in women and men: A prospective cohort study of UK Biobank participants. Diabetes Res Clin Pract. 2022; 188: 109899.
    CrossRefPubMed
  10. Kannel W. Diabetes and Cardiovascular Disease. JAMA. 1979; 241(19): 2035.
    CrossRef
  11. Jerkins T, McGill JB, Bell DSH. Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. Diabetes Obes Metab. 2023; 25 Suppl 3: 3–14.
    CrossRefPubMed
  12. Tewari A, Tewari V, Tewari J. A Cross-Sectional Study for Prevalence and Association of Risk Factors of Chronic Kidney Disease Among People With Type 2 Diabetes in the Indian Setting. Cureus. 2021; 13(9): e18371.
    CrossRefPubMed
  13. Cherney DZI, Repetto E, Wheeler DC, et al. Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. Am J Nephrol. 2020; 51(1): 74–82.
    CrossRefPubMed
  14. Maselli DB, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Adv Exp Med Biol. 2021; 1307: 171–192.
    CrossRefPubMed
  15. Kaneto H, Kimura T, Shimoda M, et al. Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: "The Earlier, the Better" in Therapy with Incretin-Based Medicine. Int J Mol Sci. 2021; 22(15).
    CrossRefPubMed
  16. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015; 1: 15019.
    CrossRefPubMed
  17. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012; 8(12): 728–742.
    CrossRefPubMed
  18. Standards of Medical Care in Diabetes. Diabetes Care. 2020; 43(Supplement_1): S1–S206.
  19. Cornell S. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. J Clin Pharm Ther. 2020; 45 Suppl 1(Suppl 1): 17–27.
    CrossRefPubMed
  20. Angeli F, Reboldi G, Poltronieri C, et al. Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. Ther Adv Cardiovasc Dis. 2015; 9(6): 412–424.
    CrossRefPubMed
  21. Kalra S, Das S, Zargar AH. A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form. Indian J Endocrinol Metab. 2022; 26(2): 98–105.
    CrossRefPubMed
  22. Kalra S. Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach. Diabetes Ther. 2014; 5(1): 333–340.
    CrossRefPubMed
  23. American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Suppl 1): S158–S178.
    CrossRefPubMed
  24. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45(11): 2753–2786.
    CrossRefPubMed
  25. Makkar BM, Kumar CV, et al. RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022. International Journal of Diabetes in Developing Countries. 2022; 42(S1): 1–143.
    CrossRef
  26. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1 Investigators. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019; 42(9): 1724–1732.
    CrossRefPubMed
  27. Rodbard HW, Rosenstock J, Canani LH, et al. PIONEER 2 Investigators. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019; 42(12): 2272–2281.
    CrossRefPubMed
  28. Mosenzon O, Blicher TM, Rosenlund S, et al. PIONEER 5 Investigators. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019; 7(7): 515–527.
    CrossRefPubMed
  29. Zinman B, Aroda VR, Buse JB, et al. PIONEER 8 Investigators. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019; 42(12): 2262–2271.
    CrossRefPubMed
  30. Rosenstock J, Allison D, Birkenfeld AL, et al. PIONEER 3 Investigators. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019; 321(15): 1466–1480.
    CrossRefPubMed
  31. Pratley R, Amod A, Hoff ST, et al. PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019; 394(10192): 39–50.
    CrossRefPubMed
  32. Pieber TR, Bode B, Mertens A, et al. PIONEER 7 investigators. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019; 7(7): 528–539.
    CrossRefPubMed
  33. Husain M, Birkenfeld AL, Donsmark M, et al. PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019; 381(9): 841–851.
    CrossRefPubMed
  34. Jacob S, Krentz AJ, Deanfield J, et al. Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. Drugs. 2021; 81(12): 1373–1379.
    CrossRefPubMed
  35. Joshi SR, Rajput R, Chowdhury S, et al. The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs. Diabetes Metab Syndr. 2022; 16(6): 102508.
    CrossRefPubMed
  36. Yabe D, Nakamura J, Kaneto H, et al. PIONEER 10 Investigators. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020; 8(5): 392–406.
    CrossRefPubMed
  37. Yamada Y, Katagiri H, Hamamoto Y, et al. PIONEER 9 investigators. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020; 8(5): 377–391.
    CrossRefPubMed
  38. Seidu S, Mellbin L, Kaiser M, et al. Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? Prim Care Diabetes. 2021; 15(1): 59–68.
    CrossRefPubMed
  39. Alsifri S, Elbadawi H, Alsabaan F, et al. Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report. Int J Clin Med. 2022; 13(1): 22–35.
    CrossRef
  40. Rajput R, Ghosh S, Banerjee S, et al. First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context. Indian J Endocrinol Metab. 2022; 26(5): 417–427.
    CrossRefPubMed
  41. Almandoz JP, Lingvay I, Morales J, et al. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clin Diabetes. 2020; 38(4): 390–402.
    CrossRefPubMed
  42. RYBELSUS (Oral Semaglutide): Highlights of Prescribing Information. https://www.novo-pi.com/rybelsus.pdf (22.08.2023).
  43. Strain WD, Frenkel O, James MA, et al. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022; 53(9): 2749–2757.
    CrossRefPubMed
  44. Brunton SA, Mosenzon O, Wright EE. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how? Postgrad Med. 2020; 132(sup2): 48–60.
    CrossRefPubMed
  45. McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023; 25(7): 1932–1941.
    CrossRefPubMed
  46. Neumiller JJ, Alicic RZ, Tuttle KR, et al. LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(9): 839–848.
    CrossRefPubMed
  47. Karalliedde J, Winocour P, Chowdhury T, et al. Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease. Br J Diabetes. 2022.
    CrossRef
  48. Mima A, Kidooka S, Nakamoto T, et al. Effects of Oral Semaglutide on Renal Function in Diabetic Kidney Disease: A Short-term Clinical Study. In Vivo. 2024; 38(1): 308–312.
    CrossRefPubMed
  49. Baekdal TA, Thomsen M, Kupčová V, et al. Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. J Clin Pharmacol. 2018; 58(10): 1314–1323.
    CrossRefPubMed
  50. Hassanein M, Almansari A, Ba-Essa E, et al. Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan. Dubai Diabetes Endocrinol. 2022; 28(4): 131–135.
    CrossRef
  51. Kalra S, Kapoor N. Oral Semaglutide: Dosage in Special Situations. Diabetes Ther. 2022; 13(6): 1133–1137.
    CrossRefPubMed
  52. Uchiyama S, Sada Y, Mihara S, et al. Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes. J Clin Med Res. 2023; 15(7): 377–383.
    CrossRefPubMed
  53. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022; 12(1).
    CrossRefPubMed
  54. Wang YW, Lin JH, Yang CS. Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Medicine (Baltimore). 2022; 101(34): e30072.
    CrossRefPubMed
  55. Meier JJ, Granhall C, Hoevelmann U, et al. Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. Diabetes Obes Metab. 2022; 24(4): 684–692.
    CrossRefPubMed
  56. Kane MP, Triplitt CL, Solis-Herrera CD. Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists. Am J Health Syst Pharm. 2021; 78(7): 556–567.
    CrossRefPubMed
  57. Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals (Basel). 2024; 17(2).
    CrossRefPubMed
  58. Villumsen M, Schelde AB, Jimenez-Solem E, et al. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine. 2021; 37: 100979.
    CrossRefPubMed
  59. Lu J, Liu H, Zhou Q, et al. A potentially serious adverse effect of GLP-1 receptor agonists. Acta Pharm Sin B. 2023; 13(5): 2291–2293.
    CrossRefPubMed
  60. Ueda P, Wintzell V, Melbye M, et al. Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study. Clin Gastroenterol Hepatol. 2024; 22(6): 1226–1237.e14.
    CrossRefPubMed
  61. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018; 10(467).
    CrossRefPubMed
  62. Rajput R, Chatterjee S, Rajput M. Can Levothyroxine Be Taken as Evening Dose? Comparative Evaluation of Morning versus Evening Dose of Levothyroxine in Treatment of Hypothyroidism. J Thyroid Res. 2011; 2011: 505239.
    CrossRefPubMed
  63. Srivastava S, Sharma G, Rathore M, et al. A Crossover Study Evaluating Effect of Timing of Levothyroxine on Thyroid Hormone Status in Patients of Hypothyroidism. J Assoc Physicians India. 2018; 66(9): 37–40.
    PubMed
  64. Evans M, Morgan AR, Bain SC, et al. Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Ther. 2022; 13(2): 225–240.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note